Skip to content

News and
Events

Sort By
  • Newest
  • Oldest
  • A to Z
  • Z to A
May 4 2016
Graybug Vision GB-102 Toxicology/PK Study Presented at ARVO 2016
Graybug Vision, Inc., a venture-stage pharmaceutical company committed to developing potentially transformative therapies for ocular diseases including wet age-related macular degeneration (AMD) and glaucoma, today announced that a second poster with new data from a preclinical study of its lead product, GB-102, a novel injectable depot formulation containing a compound...
Read More
May 2 2016
Graybug Vision Announces $44.5 Million Series B Financing
– Funding Will Support Clinical Development Activities –  Graybug Vision, a venture-stage pharmaceutical company committed to developing potentially transformative therapies for ocular diseases including wet age-related macular degeneration (AMD) and glaucoma, today announced the closing of a $44.5 million Series B financing.  The proceeds will be used to further the...
Read More
May 2 2016
Graybug Vision Collaborator Dr. Peter Campochiaro Presented at ARVO 2016
Graybug Vision, Inc., a venture-stage pharmaceutical company committed to developing potentially transformative therapies for ocular diseases including wet age-related macular degeneration (AMD) and glaucoma, today announced that data from a preclinical study of its lead product, GB-102, a novel injectable depot formulation containing a compound blocking VEGF and PDGF receptors...
Read More
Apr 25 2016
Ophthalmology Product Company Graybug Vision to Present Data at ARVO 2016
Graybug Vision, Inc., a venture-stage pharmaceutical company committed to developing potentially transformative therapies for ocular diseases including wet age-related macular degeneration (AMD) and glaucoma, today announced that data from its preclinical research will be highlighted in presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2016 Annual Meeting,...
Read More
Feb 4 2016
Ophthalmic Company GrayBug to Present at BIO CEO & Investor Conference on February 8
GrayBug, Inc., a venture-stage pharmaceutical company developing microparticle controlled release drug delivery technologies for the treatment of ocular diseases including wet age-related macular degeneration (AMD) and glaucoma, announced that Jeffrey L. Cleland, PhD, GrayBug Interim Chief Executive Officer, will present an update of the company’s progress on Monday, February 8...
Read More
Jan 29 2016
GrayBug’s Jeffrey Cleland to Present at Glaucoma 360 on January 29
GrayBug, Inc., a venture-stage pharmaceutical company developing microparticle controlled release drug delivery technologies for the treatment of ocular diseases including wet age-related macular degeneration (AMD) and glaucoma, announced that Jeffrey L. Cleland, PhD, GrayBug Interim Chief Executive Officer, will present an overview of company research at a day-long review of...
Read More
1 2 4 5 6